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Abstract 14 
The aim of the present study was to establish the between-day reproducibility of fasting plasma GLP-15 
17-36, glucagon, leptin, insulin and glucose, in lean and overweight/obese 8-11 y boys. A within-16 
groups study design was utilised wherein the boys attended two study days, separated by 1 week, 17 
where a fasting fingertip capillary blood sample was obtained. Deming regression, mean difference, 18 
Bland-Altman limits of agreement (LOA) and typical imprecision as a percentage coefficient of 19 
variation (CV %), were utilised to assess reproducibility between-days. On a group level, Deming 20 
regression detected no evidence of systematic or proportional bias between-days for all of the satiety-21 
related analytes however, only glucose and plasma GLP-17-36 displayed low typical and random 22 
imprecision. When analysed according to body composition, good reproducibility was maintained for 23 
glucose in the overweight/obese boys and for plasma GLP-17-36, in those with lean body mass. The 24 
present findings demonstrate that the measurement of glucose and plasma GLP-17-36 by fingertip 25 
capillary sampling on a group level, is reproducible between-days, in 8-11 y boys. Comparison of 26 
blood glucose obtained by fingertip capillary sampling can be made between lean and 27 
overweight/obese 8-11 y boys. Presently, the comparison of fasting plasma GLP-17-36 according to 28 
body weight is inappropriate due to high imprecision observed in lean boys between-days. The use of 29 
fingertip capillary sampling in the measurement of satiety-related analytes, has the potential to 30 
provide a better understanding of mechanisms that affect appetite and feeding behaviour in children. 31 
 32 
Keywords 33 
GLP-17-36; Insulin, Glucagon; Leptin; Glucose; Satiety. 34 
 35 
 36 
  37 
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1. Introduction 38 
Human appetite and the regulation of feeding behaviour are sophisticated processes. Emerging 39 
evidence confirms the control of appetite and regulation of feeding behaviour is primarily governed 40 
through interaction between the nervous and digestive systems, via the enteric nervous system (ENS) 41 
[1]. There are numerous analytes which elicit episodic (short-term) and tonic (long-term) properties, 42 
relaying information through the gut-brain axis to regulate satiety. The present work will focus on 43 
glucagon-like-peptide 1 (GLP-17-36), glucagon, glucose (episodic analytes), insulin and leptin (tonic 44 
analytes). The aforementioned analytes represent several commonly measured metabolic variables 45 
documented as having fundamental roles in satiety signalling [2] and thus contribute to human energy 46 
balance [3-6].  47 
During consumption of a meal, GLP-17-36 is released by the endocrine L-cells as nutrients are detected 48 
in the duodenum. Appearance of GLP-17-36 in the circulation is bi-phasic, occurring within 10 to 15 49 
minutes [7, 8] and at 30 to 60 minutes [9] following ingestion. The effects of GLP-17-36 via the ENS are 50 
to inhibit gastric emptying and intestinal motility, a process termed the ‘ileal brake’ which brings 51 
about meal termination [6]. Levels of circulating GLP-17-36 can be elevated for more than 3 h following 52 
a meal [10]. It has been suggested that GLP-17-36 not only acts to restrict food intake but also functions 53 
to extend the time before any further eating episode can occur [10]. Recent evidence indicates that 54 
glucagon is able to signal the brain through vagal afferent neurons, to effect meal termination and may 55 
also decrease meal size [11]. Primarily glucagon opposes the actions of insulin [11, 12] which is released 56 
due to the detection of glucose in the blood. The main function of insulin in satiety therefore, is to 57 
enable uptake of glucose and reduce levels of the blood sugar [13] in accordance with the ‘Glucostatic 58 
theory’ [14]. The short-term actions of GLP-17-36, insulin and glucagon, are in contrast to leptin which 59 
has long term anorectic properties. Leptin is an adipokine largely produced by adipocytes and is 60 
correlated with white adipose tissue [15]. When an individual is in a positive energy balance state, 61 
circulating plasma leptin is increased which facilitates a reduction in food intake, until energy balance 62 
is restored [12]. Leptin also has specific short term functions that bring about a reduction in meal size. 63 
It appears to do this by acting on taste sensitivity through the hyperpolarization of taste buds on the 64 
tongue [16] which reduces the positive reinforcing effects of food ingestion on the brain [17].  65 
In England, 19.1% of children are currently obese [18] and it appears to have greater prevalence in boys 66 
during mid-to-late childhood (8-11 y) [19]. Assessment of the aforementioned analytes in paediatric 67 
populations could provide essential information in relation to the regulation of appetite and feeding 68 
behaviour in children. To the author’s knowledge, appetite research that quantifies glucose, GLP-17-36, 69 
insulin, glucagon and leptin in healthy paediatric populations, particularly 8-11 y boys is sparse and is 70 
likely due to the sampling methods invariably utilised. 71 
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Generally, in research and clinical practice, blood is obtained by antecubital-venous or arterio-venous 72 
sampling. For research with vulnerable populations such as children, antecubital-venous sampling is 73 
invasive and may even be deemed as unethical. Recent research from our laboratory has examined the 74 
agreement and reproducibility of plasma GLP-17-36, glucagon, leptin and insulin, between fingertip 75 
capillary blood and antecubital-venous sampling in healthy adults [20]. Green and colleagues (2014) [20] 76 
demonstrated that fingertip capillary blood sampling provided a comparable and reproducible 77 
alternative to antecubital-venous, to quantify glucagon and to lesser degree, GLP-17-36, leptin and 78 
insulin. Such a method is far less invasive than venous sampling, and thus represents a more suitable 79 
procedure for use in paediatric populations [20].  80 
To the best of our knowledge, evidence of between-day reproducibility in fasted plasma GLP-17-36, 81 
glucagon, leptin and insulin exists only for healthy adults, for traditional methods of blood sampling 82 
[10, 21, 22] and fingertip capillary sampling [20]. Currently, there is no understanding of between-day 83 
reproducibility of fasted plasma GLP-17-36, glucagon, leptin and insulin obtained from fingertip 84 
capillary blood in children. In view of the less invasive nature of fingertip capillary sampling, prior to 85 
short-term intervention in appetite-related studies with children, it seems prudent to establish 86 
between-day reproducibility in fasted levels of these analytes of interest. Knowledge of the between-87 
day reproducibility will inform researchers whether changes are due to intervention and not 88 
imprecision related to sample handling, analytical procedures and equipment, or disparity in 89 
biological responses. Consequently, the aim of the present study is to establish the between-day 90 
reproducibility of fasting plasma GLP-17-36, glucagon, insulin, leptin and blood glucose obtained by 91 
fingertip capillary sampling, in 8-11 y lean and overweight/obese boys.      92 
2. Methods 93 
2.1. Study design 94 
A within-groups study design was utilised to establish between-day reproducibility in fasting plasma 95 
GLP-17-36, glucagon, insulin and leptin and blood glucose obtained from fingertip capillary blood, in 96 
8-11 y old boys.  97 
The study was conducted according to 2013 Declaration of Helsinki (World Medical Association. 98 
2013) and was approved by the University of Northumbria, Faculty of Health and Life Sciences 99 
Ethics Committee. Written informed consent was obtained from each child’s parent or main carer and 100 
assent was given by the child prior to data collection. 101 
 102 
2.2. Participants 103 
Boys aged 8-11 y were recruited from a primary school located within the city of Newcastle upon 104 
Tyne (North East England, UK). To enable recruitment, consent was obtained from the Head Teacher 105 
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of the school they attended. A recruitment pack was distributed to all eligible boys who expressed an 106 
interest in participating and they were asked to take this home to their parent (or main carer). The 107 
pack contained a letter addressed to their parent/main carer with a full explanation of the study and 108 
consent forms for them and their child (if able) to sign and return to school. Signed consent was 109 
received from 24 boys, of which 23 participated in the study. Boys were excluded from participating 110 
if they were diabetic or took any form of medication known to affect taste, smell or appetite. 111 
 112 
2.3. Study protocol 113 
Prior to the first visit to the University laboratory, each boy was provided with a food diary. With the 114 
help of their parent (or main carer) they were requested to weigh and record all foods and fluids 115 
consumed from 1700 h the day before each visit until 2100 h, at which point they were required to 116 
begin a 12 h overnight fast. Following the first visit, they were provided with a copy of the food diary 117 
so that their food and fluid intake could be replicated prior to visit two. With the assistance of the 118 
parent (or main carer) they were asked to refrain from sport or physical activity from 1700 h until 119 
arrival at school on the morning of each visit.  120 
The boys were required to attend the University laboratory on two different days, separated by 1 121 
week. On the morning of each visit, following a 12 h overnight fast, the boys attended school at 0830 122 
h. From waking, they were permitted to drink only water and with the assistance of their parent (or 123 
main carer) were asked to note this amount in the food diary to enable replication prior to the second 124 
visit. For logistical reasons, the boys were organised into testing groups of five to seven. At school 125 
(0830 h), the boys were met by two members of the research team and transported to the University 126 
for 0845 h so that they could each provide one fasted capillary blood sample.   127 
During the first visit, the stature and seated height of each boy was measured to the nearest 0.01 m 128 
using a Harpenden Portable Stadiometer (Holtain Limited, Pembs, UK) to calculate age (y) from peak 129 
height velocity (APHV) [23]. Body mass was measured to the nearest 0.1 kg using portable SECA 130 
scales (SECA United Kingdom) whilst wearing light clothing. Waist circumference was measured to 131 
the nearest 0.01 m with a non-elastic flexible tape at each boy’s natural waist whilst standing, as a 132 
measure of central adiposity [24]. In both visits, immediately following the collection of the blood 133 
sample, each boy was provided with breakfast, after which they were escorted back to school by two 134 
researchers. 135 
 136 
2.4. Blood sampling 137 
To obtain blood samples, the same fingertip capillary blood sampling and handling method utilised by 138 
Green and colleagues [20] was followed. Prior to blood collection, 33 µL per mL of aprotinin and 30 139 
µL per mL of DPP-IV inhibitor were added to a microvette and pre-cooled, to prevent the cleavage of 140 
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GLP-17-36 by proteases and thus aid in the preservation of this analyte. The fingertip was pierced with 141 
a sterile automated lancet (Accu-Check, Mannheim, Germany) and blood was collected (300 µL) into 142 
a pre-cooled EDTA microvette. Immediately following blood collection, the microvettes were placed 143 
on ice and then spun at 1500 g for 10 min in a multispeed microcentrifuge. Aliquots of the plasma 144 
supernatant were pipetted into labelled Eppendorfs and stored at −80 °C for quantification of GLP-17-145 
36, glucagon, leptin and insulin at a later time-point. Together with the fingertip capillary blood 146 
sample, a further 20 µL of whole blood was collected from the same puncture site into sodium 147 
heparinized capillary tubes and transferred into Eppendorfs containing 1 mL haemolysis solution 148 
(EKF Diagnostics) to determine blood glucose. Samples were subsequently shaken to encourage 149 
haemolysis, placed on ice and processed immediately. 150 
 151 
2.5. Blood analysis 152 
The concentrations of GLP-17-36 (pg/mL), glucagon (pg/mL), leptin (pg/mL) and insulin (pmol/L) 153 
were determined by electrochemiluminescence, using a human hormone multiplexed sandwich 154 
immunoassay (Sector Imager 2400, MesoScale Discovery, Rockville, MD. USA). In preparation for 155 
the measurement of GLP-17-36 (pg/mL), glucagon (pg/mL), leptin (pg/mL) and insulin (pmol/L), a 156 
stock calibrator was diluted (fourfold serial diutions) with a Metabolic Assay Working Solution 157 
(provided by the manufacturer), to create an eight point standard curve. As advised by the 158 
manufacturer, the calibrators and the fingertip capillary plasma samples were analysed in duplicate on 159 
one assay plate to eliminate inter-assay variation. Forty µL of plasma supernatant was extracted from 160 
each Eppendorf and pipetted into each well. The multiplex assay uses capture antibodies namely, anti-161 
GLP-1 (7-36) amide, anti-insulin, anti-glucagon and anti-leptin, in solution. The capture antibodies and 162 
the fingertip capillary plasma samples are added to an electroluminescent compound (MSD SULFO-163 
TAG™ label). Over two incubation periods, GLP-17-36 (pg/mL), glucagon (pg/mL), leptin (pg/mL) 164 
and insulin (pmol/L) along with the electroluminescent compound, bind to their specific capture 165 
antibody onto a working electrode surface located within each well. A read buffer solution is then 166 
added to provide the appropriate chemical environment for electrochemiluminescence and to enable a 167 
voltage to be applied to the plate electrodes which causes the labels on the electrode surface to emit 168 
light. The intensity of light emitted, is measured.  169 
 170 
The lower limits of detection (sensitivity) for GLP17–36, glucagon, leptin and insulin were, 1.0 pg/mL, 171 
20 pg/mL, 22 pg/mL and 9.0 pmol/L respectively, as specified by the manufacturer. Intra-assay 172 
coefficients of variation (CV) were established by the measurement of one, fasted fingertip capillary 173 
plasma sample, three times on the same assay plate. For GLP-17-36, glucagon, leptin and insulin, these 174 
were established as 11%, 9%, 19% and 11%, respectively. 175 
 176 
7 
 
Blood glucose was quantified by the glucose oxidase method using an automated point of care 177 
glucose analyser (BiosenC_line, EKF Diagnostics). The method electro-chemically measures β-D-178 
glucose as it is converted to gluconic acid. Prior to use, the analyser was calibrated with a solution of 179 
known glucose concentration (12 mmol/L). 180 
 181 
2.6. Statistical analysis 182 
For all boys and when split according to lean and overweight/obese body composition, means ±SEM 183 
were calculated for GLP-17-36, glucagon, leptin, insulin and glucose. Within-subject reproducibility 184 
between samples for visits one and two was assessed by utilising a range of statistical methods. 185 
Deming regression tests for and provides a value for average systematic and proportional bias on a 186 
group level [25]. Mean difference, provides a value for typical error [26]. Bland-Altman limits of 187 
agreement (LOA) [27] was also used to indicate relative bias (mean difference) and random 188 
imprecision. Typical imprecision as a percentage coefficient of variation (CV %) was also calculated 189 
to quantify random imprecision. All values were checked for heteroscedasticity by the examination of 190 
box plots, scatter plots and related Pearson’s correlation coefficients of the absolute differences 191 
(imprecision) and the means of measurements [27]. If heteroscedasticity was apparent with an r value 192 
of 0.4, the data was log transformed (natural) and stated as a geometric mean and ratio (x/÷) LOA. 193 
To aid in the interpretation of the statistical analysis, clinically significant differences deemed to be 194 
meaningful were acquired for each analyte in advance of data collection. The clinically significant 195 
differences utilised were based on published adult research that had explored the effects of food 196 
intake, appetite or within subject reliability of fingertip sampling, in relation to GLP-17-36, glucagon, 197 
leptin, insulin or glucose [10, 21, 22, 28]. The use of clinically meaningful differences based on adult data 198 
was due to the lack of reproducibility literature to date, for healthy children. Due to the adult studies 199 
being largely conducted over set time periods, the clinically meaningful values obtained were time-200 
averaged area under the curve [AUC]. The values were therefore determined to be 2.1 pg/mL, 7.4 201 
pg/mL [10, 28], 222.0 pg/mL [21], 4.8 pmol/L and 0.5 mmol/L[22] respectively, for GLP-17-36, glucagon, 202 
leptin, insulin and glucose respectively.  203 
3. Results 204 
3.1. Participant characteristics 205 
A total of 23 boys took part in the study however, two were excluded from statistical analysis due to 206 
non-standardisation of food intake prior to their second visit. In addition, owing to issues related to 207 
blood collection, results for GLP-17-36, leptin, insulin and glucose are provided for 20 boys and for 208 
glucagon, 17 boys. Participant characteristics are presented in Table 1. According to UK age and sex-209 
specific BMI centiles [29], the majority of boys were classified as having a healthy body mass (76%) 210 
and 24% were classified as overweight/obese. Mean age (y) at peak height velocity (APHV) was        211 
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-3.4±0.2 y and -3.2±0.3 for the lean and overweight/obese boys, respectively. The APHV of the lean 212 
boys indicated they were an average of 3 y and 4.8 months and the overweight/obese boys were an 213 
average of 3 y 2.4 months, from reaching their peak height velocity. 214 
 215 
Table 1. Participant characteristics.  216 
Participant characteristic Lean boys  
(n = 16) 
Overweight/obese 
boys (n=5) 
Age (y) 10.5±0.2 10.3±0.3 
Body mass (kg) 34.9±1.0 47.6±3.6 
Stature (m) 1.45±0.0 1.44±0.0 
BMI (kg/m2) 16.6±0.3 22.8±0.9 
Waist circumference (cm) 60.4±1.0 74.1±3.0 
Age at peak height velocity (y) -3.4±0.2 -3.2±0.3 
 217 
3.2. Reproducibility of GLP-17-36, glucagon, leptin, insulin and glucose 218 
3.2.1. Deming regression 219 
In relation to reproducibility for all boys between visits one and two, Deming regression analysis 220 
revealed no evidence of systematic [intercept (95% confidence interval (CI)] or proportional bias 221 
[slope (95% CI)] in fasted plasma concentrations of any of the analytes or glucose. For GLP-17-36, the 222 
intercept (95% CI) was -0.1 (-2.2 to 2.1) and slope (95% CI) was 0.9 (0.5 to 1.4) (Figure 5.1A), 223 
glucagon intercept (95% CI)  was 1.4 (-45.9 to 48.8)] and slope (95% CI) was 1.1 (0.7 to 1.5) (Figure 224 
5.1B), leptin intercept (95% CI) was -2549 (-7260 to 2162) and slope (95% CI) was 1.5 (0.9 to 1.9) 225 
(Figure 5.1C), insulin intercept (95% CI) was -204.6 (-23.1 to 315.5) and slope (95% CI) was 0.8 (0.3 226 
to 1.1) (Figure 5.1D) and for glucose the intercept (95%) was 2.1 (-3.6 to 7.8) and slope (95% CI) was 227 
0.6 (-0.6 to 1.8) (Figure 5.1E). 228 
When split according to body composition, Deming regression analysis of fasted plasma 229 
concentrations for the lean boys revealed no evidence of systematic [intercept (95% (CI)] or 230 
proportional bias [slope (95% CI)] for GLP-17-36, glucagon and insulin (Table 2). For leptin, there was 231 
evidence of a proportional difference, whilst for glucose there was a significant difference between 232 
visits one and two (Table 2). For the overweight/obese boys, there was no evidence of systematic 233 
[intercept (95% (CI)] or proportional bias [slope (95% CI)] for GLP-17-36, glucagon, leptin and 234 
glucose (Table 2). For insulin, there was evidence of a proportional bias between visits one and two 235 
(Table 2). 236 
 237 
 238 
 239 
 240 
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 241 
Figure 2. Deming regression scatter-plots of fasted plasma GLP-17-36 (pg/mL, panel A), glucagon (pg/mL, panel B), leptin 242 
(pg/mL, panel C), insulin (pmol/L, panel D) and glucose (mmol/L, panel E) for visit one versus visit two.  The solid black line 243 
indicates the line of equality. The dashed line represents the regression line with the corresponding 95% CI falling in between 244 
the black dotted lines. Individual data points denote means of visit one versus visit two for fasted plasma GLP-17-36, glucagon, 245 
leptin, insulin and glucose. For conversion of GLP-17-36 (pg/mL) and insulin (pg/mL) to SI units, multiply by 0.298 and 0.172, 246 
respectively. 247 
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Table 2. Deming regression analysis between visits one and two of the lean (n=16) and (n=5) 248 
overweight/obese 249 
 
Analyte 
Lean only Overweight/obese only 
Intercept (95% CI) Slope (95% CI) Intercept (95% CI) Slope (95% CI) 
GLP-17-36 
(pg/mL) 
-1.0  
(-2.7 to 0.8) 
1.0  
(0.7 to 1.4) 
4.3  
(-9130 to 9298) 
-18.0  
(-1865 to 1829) 
Glucagon 
(pg/mL) 
3.3  
(-60.5 to 54.0) 
1.1  
(0.6 to 1.5) 
7.8  
(-141.3 to 157.0) 
1.0 
(-0.0 to 2.0) 
Insulin 
(pmol/L) 
-24.5 
(-8.3 to 39.4) 
1.5 
(0.5 to 2.6). 
55.2  
(-9.2 to 119.7) 
0.4 
(-0.1 to 0.9) 
Leptin 
(pg/mL) 
416.6  
(-782.2 to 1615.0) 
0.7  
(0.4 to 0.9) 
36654.0  
(-47208.0 to 120517.0) 
-1.2 
(-6.4 to 4.0) 
Glucose 
(mmol/L) 
4.7  
(1.3 to 8.2) 
0.7  
(-0.6 to -0.8). 
-3.0 
(-18.4 to 12.4) 
1.6 
(-1.5 to 4.8) 
 250 
3.2.2. Bland-Altman limits of agreement (LOA, mean difference and typical imprecision (CV %) 251 
Table 3 displays the mean ±SEM of all analytes for visits one and two, as well as mean differences, 252 
typical imprecision expressed as a percentage coefficient of variation (CV %) and Bland Altman 253 
LOA. Between visits one and two, the CV % for plasma GLP-17-36, glucagon, leptin and insulin were 254 
high, and low for plasma glucose. Bland-Altman LOA enabled the calculation between visits of 255 
relative bias (mean difference) ± random imprecision (1.96 standard deviations (SD) of the 256 
difference). As such LOA showed good agreement between visits one and two for plasma GLP-17-36, 257 
although there was large random imprecision. Limits of agreement for plasma glucagon, leptin and 258 
insulin exceeded the aforementioned predetermined clinical values and showed large random 259 
imprecision.  For glucose, LOA were good between visits and random imprecision was low. 260 
The means ±SEM for visits one and two, mean differences, typical imprecision (CV %) and Bland 261 
Altman LOA for all analytes when split according to lean and overweight/obese body composition, 262 
are displayed in Table 4. When compared with the predetermined clinical values, the LOA for the 263 
lean boys of GLP-17-36, glucagon, leptin and glucose showed good reproducibility, whilst insulin 264 
showed poor reproducibility between visits one and two. For the overweight/obese boys, the LOA 265 
showed good reproducibility for GLP-17-36 and glucose, whilst for glucagon, insulin and leptin 266 
reproducibility remained poor, between visits. 267 
   268 
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    Table 3. Means ±SEM, mean differences ±SEM and CV % between visit one and visit two of fasting plasma GLP-17-36 (pg/mL), glucagon (pg/mL),  269 
     leptin (pg/mL), insulin (pmol/L) and glucose (mmol/L) for all boys (n=21). 270 
 GLP-17-36  
(pg/mL) 
Glucagon  
(pg/mL) 
Leptin  
(pg/mL) 
Insulin  
(pmol/L) 
Glucose  
(mmol/L) 
Visit one mean ±SEM 4.7±0.6 92.8±18.0 6679.8±1582.9 63.0±10.0 4.9±0.1 
Visit two mean ±SEM  4.6±0.7 101.5±19.1 7218.4±2169.4 70.2±8.0 5.0±0.1 
Mean difference ±SEM 0.1±0.1 8.7±1.1 746.9±586.5 7.2±2.0 0.1±0.0 
CV % 68.8 45.0 57.0 48.7 5.3 
Bland-Altman LOA -0.5±3.3 8.5±93.1 538.3±11209.2 7.2±67.3 0.1±0.7 
SEM standard error mean; CV % percentage coefficient of variation. 271 
 272 
 273 
Table 4. Means ±SEM, mean differences ±SEM, CV % and Bland-Altman limits of agreement between visit one and visit two of fasting plasma GLP-17-36 (pg/mL), glucagon 274 
(pg/mL), leptin (pg/mL), insulin (pmol/L) and glucose (mmol/L) for lean (n=16) and overweight/obese boys (n=5). 275 
  GLP-17-36  
(pg/mL) 
Glucagon  
(pg/mL) 
Leptin  
(pg/mL) 
Insulin  
(pmol/L) 
Glucose  
(mmol/L) 
 
 
Lean 
Visit one mean ±SEM 4.7±0.7 89.1±19.3 3397.8±802.3 56.3±6.4 5.0±0.1 
Visit two mean ±SEM 3.9±0.8 98.8±21.7 2647.4±565.8 62.0±8.4 5.1±0.1 
Mean difference ±SEM 0.9±0.1 9.7±2.4 750.4±236.5 3.8±2.0 0.1±0.0 
CV % 41.5 45.8 53.3 32.8 5.2 
Bland-Altman LOA 0.8±1.4 6.4±50.5 32.6±150.8 5.2±26.0 -0.1±0.4 
 Visit one mean ±SEM 4.3±1.5 109.1±57.4 15307.2±2940.9 98.6±45.7 4.8±0.2 
 Visit two mean ±SEM 7.5±1.9 113.8±55.8 17596.3±3348.2 96.8±20.3 4.9±0.4 
Overweight/obese Mean difference ±SEM 3.2±0.4 4.7±37.3 2289.1±407.3 1.7±25.4 0.1±0.2 
 CV % 78.5 59.6 67.3 72.7 4.7 
 Bland-Altman LOA 3.2±0.5 4.7±37.3 -10.15±323.8 -1.7±55.8 0.1±0.3 
SEM standard error mean; CV % percentage coefficient of variation. 276 
12 
 
4. Discussion 277 
To the authors’ knowledge, this is the first study to examine between-day reproducibility of fasted 278 
plasma satiety-related analytes, namely GLP-17-36, glucagon, leptin, insulin and glucose, in 8 to 11 y-279 
old boys. The results provide initial data for between-day reproducibility in the above mentioned 280 
analytes and also for glucose when obtained by fingertip capillary sampling, from children. The main 281 
findings showed that for all boys, glucose and GLP-17-36 are reproducible between-days, when 282 
obtained by fingertip capillary sampling from 8-11 y boys. When analysed according to body 283 
composition, between-day reproducibility was maintained for GLP-17-36 in the lean boys and for 284 
glucose, in those classified as overweight/obese. Comparison of blood glucose between lean and 285 
overweight/obese children is therefore possible when obtained by fingertip capillary sampling. For 286 
fingertip derived GLP-17-36 however, comparison is not advised according to body composition due to 287 
greater imprecision established between-days in overweight/obese boys. The reproducibility data 288 
obtained presently could provide important information with regards to appetite-related research with 289 
children. Fingertip capillary sampling of glucose and GLP-17-36 might also be a feasible alternative to 290 
the more invasive methods of blood draw, in future paediatric appetite-related research. 291 
For all boys, fasting glucose was found to be the most reproducible between-days, illustrating that the 292 
analyte can be reliably measured by fingertip capillary sampling, in paediatric appetite-related 293 
intervention studies. When examined according to body composition, the strong reproducibility of 294 
glucose was maintained, but only in the overweight/obese boys. In the lean boys, there was evidence 295 
of systematic and proportional bias between-days, although all other statistical tests supported good 296 
reproducibility. As individual values for both visits for the lean boys were within the normal range for 297 
fasting blood glucose [30], this suggests that comparison of the analyte can be made between lean and 298 
overweight/obese groups, when utilising fingertip capillary sampling. This is important due to the 299 
associations of glucose with satiety, as according to the ‘glucostatic theory’[14], the presence of this 300 
analyte instigates insulin release so that the sugar may be absorbed [13]. Along with insulin, other 301 
hormones are simultaneously released such as GLP-17-36, the actions of which restrict food intake [31]. 302 
The results of the present study thus demonstrate the necessity for inclusion and measurement of 303 
glucose in acute appetite-related clinical studies with children.   304 
Fasting plasma GLP-17-36 also showed good between-day reproducibility, apart from displaying a high 305 
CV %. The CV % (68.8%) showed typical imprecision to be threefold greater than found previously 306 
in adults (22.7%) when utilising fingertip capillary sampling [20]. When split by body composition, the 307 
reproducibility of GLP-17-36 was noted to improve for the lean boys, although typical imprecision (CV 308 
41.5%) was still almost double than established in adults (CV 22.7% and 19.0 %) [20, 32]. Presently 309 
however, only one fingertip capillary sample was collected from the boys in each visit. In our most 310 
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recent study with adults, we collected five samples over 120 min [20] which may explain the reduced 311 
variation in values [26]. For the overweight/obese boys, imprecision between-days was further 312 
increased, as greater values were obtained for mean difference (3.2±0.4 pg/mL), CV % (78.5%) and 313 
Bland-Altman (LOA) (3.2±0.5 pg/mL). Previous adult reproducibility testing of GLP-17-36 has shown 314 
that a difference of 2.1 pg/mL [33] would be deemed clinically meaningful [10]. The plasma 315 
concentrations of  GLP-17-36 determined presently, were within the range of those found previously 316 
for fasted 8-12 y boys, during resting conditions  (median 9.9, interquartile range 4.3 to 24.7 pg/mL) 317 
[34]. Therefore, these results would suggest that plasma GLP-17-36 can be measured by fingertip 318 
capillary sampling in lean 8-11 y boys. In view of the previous adult reproducibility findings and the 319 
greater imprecision established in the present study for overweight/obese boys, the comparison of 320 
fasting plasma GLP-17-36 in children when split according to body composition, is not advised when 321 
obtained by this less invasive method.  322 
In contrast to glucose and GLP-17-36, the reproducibility of insulin, glucagon and leptin was poor for 323 
all boys. Despite Deming regression analysis displaying no systematic or proportional bias, typical 324 
and random imprecision between-days on a group level, was high. The findings thus demonstrate that 325 
fasting values of insulin, glucagon and leptin are likely to alter research interpretation if fingertip 326 
capillary sampling is employed over venous methods. When the boys were spilt by body composition, 327 
there was an increase both in mean values and in overall imprecision in the overweight/obese boys for 328 
glucagon, leptin and insulin. Furthermore, Deming regression showed proportional bias between-days 329 
for insulin in those classified as overweight/obese and for leptin in the lean boys. These results 330 
suggest that as concentrations of leptin and insulin rise, imprecision also increases and thus illustrates 331 
that fingertip capillary values of fasting leptin and insulin cannot be compared between lean and 332 
overweight/obese children. Reasons for the high typical imprecision, could be that both leptin and 333 
insulin are tonic peptides which indicate long term nutritional status. The actions of leptin in 334 
particular, are to signal the brain as to the status of adiposity and so levels of this analyte increase 335 
according to body mass [35]. Fasting levels of insulin alongside glucose are known to increase with 336 
pubertal change [36] and earlier pubertal transition can be triggered by increased adiposity [37]. 337 
However, it should be noted, that as sampling was only 7 days apart, it is unlikely that extensive body 338 
mass or pubertal dependent changes in insulin and glucose would have occurred in the present 339 
population, on an intra-individual basis. 340 
The between-day reproducibility of glucagon remained poor for the lean boys when split according to 341 
body composition. For those classified as overweight/obese, there was a slight improvement in 342 
reproducibility as shown by a decrease in mean difference and Bland-Altman LOA. For this analyte 343 
however, there was a lower number of participants in the lean and overweight/obese groups and this 344 
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may have contributed to the poor reproducibility [26]. Further reproducibility testing of fingertip 345 
capillary sampled glucagon in paediatric populations is therefore, warranted.  346 
The finding that fasting concentrations of glucose can be compared between lean and 347 
overweight/obese 8-11 y boys, demonstrates the practical application of the measurement of this 348 
analyte by fingertip capillary sampling in future appetite-related intervention research. Most notable 349 
however, is that fasting concentrations of GLP-17-36 can also be measured in lean 8-11 y boys, by this 350 
less invasive method. Although research suggests that fasting concentrations of GLP-17-36 are similar 351 
in lean, overweight and obese children [34, 38, 39], there is a dearth of evidence in relation to post-352 
prandial responses [40]. Adult studies suggest that the post-prandial response of GLP-17-36 is blunted in 353 
obesity [9]. To date, it is unclear whether the post-prandial response of GLP-17-36 is blunted in obese 354 
children also [9, 38, 39]. Investigation into the reproducibility of post-prandial satiety-related responses, 355 
which include GLP-17-36 when obtained by fingertip capillary sampling is therefore, warranted in 356 
children. In doing so, fingertip capillary sampling of satiety-related analytes alongside subjective 357 
measurement with visual analogue scales (VAS) could enable more rigorous investigations of 358 
paediatric appetite. A consequence of this might be a better understanding of the mechanisms which 359 
affect paediatric appetite and subsequent feeding behaviour which may have a role in obesity.   360 
As this was the first study to measure between-day reproducibility of GLP-17-36, glucagon, leptin and 361 
insulin in a paediatric population, it is not without limitations. Firstly, this meant that findings had to 362 
be directly compared with those of adults, as this was the only available data. Concentrations of 363 
various hormones including insulin and leptin differ with age and sex and so a proportion of the 364 
imprecision noted in this study, could be due to biological events linked to pubertal status [41]. Such a 365 
dynamic could successively affect the comparison of GLP-17-36 and glucagon. In addition, some 366 
analytical imprecision may have occurred. To prevent this, the pre-treatment, sample handling and 367 
analysis were all rigorously controlled, as demonstrated by the low intra-assay coefficients of 368 
variation (CV) obtained for GLP-17-36 (11%), glucagon (9%) and insulin (11%). In the present study, 369 
it is not known whether the levels of any of the fasted analytes could have been affected by stress, as 370 
this psychological marker was not measured. However, to counteract any stress the boys may have 371 
felt prior to blood draw, the University laboratory was arranged to resemble a kitchen in the home. 372 
The blood sampling area was hidden from view and only those children who were entirely 373 
comfortable with the procedure participated. Future reproducibility investigations utilising fingertip 374 
capillary sampling, might therefore benefit from the additional measurement of cortisol. Nevertheless, 375 
at the time of writing, there are no paediatric studies that have measured between day reproducibility 376 
of GLP-17-36, glucagon, leptin and insulin, when utilising fingertip capillary sampling. Indeed the use 377 
of fingertip capillary sampling in this study is a strength and is a technique which reduces ethical 378 
concerns surrounding blood sampling in paediatric populations, particularly in comparison to the 379 
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more invasive venous sampling [20]. Consequently, the study findings enable the opportunity for future 380 
investigations to utilise fingertip capillary blood sampling to quantify, GLP-17-36 and glucose, 381 
particularly with vulnerable populations such as paediatrics. The study also employed several 382 
statistical tests to provide a more thorough examination which included Deming regression analysis, a 383 
preferred statistical test employed in clinical research, as opposed to a t-test and Pearson’s correlation. 384 
To conclude, for all boys, fingertip derived glucose and GLP-17-36 were reproducible between-days. 385 
The good reproducibility of glucose enables the comparison of this analyte between lean and 386 
overweight/obese 8-11 y boys. Decreased reproducibility of GLP-17-36 in lean boys, in comparison to 387 
those classified as overweight/obese however, suggests that this analyte should not be compared 388 
between these two groups. The present findings offer the opportunity for researchers to utilise less 389 
invasive fingertip derived concentrations of glucose and GLP-17-36 in future paediatric satiety-related 390 
investigations. Measurement of both glucose and GLP-17-36 by fingertip capillary sampling could not 391 
only provide more rigorous investigation but also increase the practical application of paediatric 392 
appetite findings. Moreover, a better understanding of the mechanisms that have an affect on appetite 393 
and feeding behaviour in children, a population that is currently at increasing risk of obesity. 394 
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